28 JUNE 2024, KUALA LUMPUR – Arcadia Life Sciences Sdn Bhd (ARCADIA) is proud to announce the launching of the SHINE Program, in collaboration with Revvity Singapore Pte Ltd (REVVITY) and with the support of the Malaysian Patients’ Organization for Primary Immunodeficiencies (MYPOPI). SHINE (which stands for Screening for Health, Intervention, and Nurturing of Every Child) Program aims to avail newborn babies in Malaysia and Southeast Asian (SEA) regions access to expanded Newborn Screening (ENBS) which includes the comprehensive testing of newborns for a wide range of genetic, metabolic, and congenital disorders.
Likewise, the President of MYPOPI, Mr Bruce Lim Wee Diong reiterated that ENBS through the SHINE program would be a game changer to allow access to timely diagnosis and appropriate treatment for children suffering from serious and life-threatening disorders. This landmark collaboration hopes to ensure that all babies can have equitable access to newborn screening; a life-saving tool for conditions such as Severe Combined Immunodeficiency (SCID) which is in line with Malaysia’s national policy on Rare Diseases.
ARCADIA is hopeful that the SHINE Program will lead to raising more awareness and coverage for rare and metabolic diseases such as Severe Combined Immunodeficiency (SCID), Spinal Muscular Atrophy (SMA), X-linked agammaglobulinemia (XLA) and Inborn Errors of Metabolism (IEM) in Malaysia and SEA Region. ARCADIA aims to screen 20,000 newborns over the next two years using the ENBS platform. Let us seize this opportunity to collaborate, innovate, and advocate for the effective implementation of this program.
Together, we can create a healthier, brighter future for our children and generations to come.
Act Now for tomorrow’s future.
Photo Media
